Vor Ort
Merkzettel Warenkorb
Produktbild: Oxidative Stress and Neuroprotection
Band 71

Oxidative Stress and Neuroprotection

Aus der Reihe Journal of Neural Transmission. Supplementa

194,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

15.09.2006

Abbildungen

XIV, 264 p.

Herausgeber

S.H. Parvez + weitere

Verlag

Springer Wien

Seitenzahl

264

Maße (L/B/H)

28,3/21,5/2,3 cm

Gewicht

1029 g

Auflage

2006

Sprache

Englisch

ISBN

978-3-211-33327-3

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

15.09.2006

Abbildungen

XIV, 264 p.

Herausgeber

Verlag

Springer Wien

Seitenzahl

264

Maße (L/B/H)

28,3/21,5/2,3 cm

Gewicht

1029 g

Auflage

2006

Sprache

Englisch

ISBN

978-3-211-33327-3

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Oxidative Stress and Neuroprotection
  • Levodopa in the treatment of Parkinson’s disease.- Changing dopamine agonist treatment in Parkinson’s disease: experiences with switching to pramipexole.- The DONPAD-study — Treatment of dementia in patients with Parkinson’s disease with donepezil.- PD-related psychosis: pathophysiology with therapeutical strategies.- Antioxidant capacity in postmortem brain tissues of Parkinson’s and Alzheimer’s diseases.- Apoptosis inhibition in T cells triggers the expression of proinflammatory cytokines — implications for the CNS.- Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson’s disease: possible implications of glial cells.- Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection.- The relationship of early studies of monoamine oxidase to present concepts.- Isatin, an endogenous MAO inhibitor, and a rat model of Parkinson’s disease induced by the Japanese encephalitis virus.- Isatin interaction with glyceraldehyde-3-phosphate dehydrogenase, a putative target of neuroprotective drugs: partial agonism with deprenyl.- Inhibition of amine oxidases by the histamine-1 receptor antagonist hydroxyzine.- Neuroprotection for Parkinson’s disease.- Marker for a preclinical diagnosis of Parkinson’s disease as a basis for neuroprotection.- Assessing neuroprotection in Parkinson’s disease: from the animal models to molecular neuroimaging in vivo.- Deprenyl: from chemical synthesis to neuroprotection.- The use of rasagiline in Parkinson’s disease.- Novel neuroprotective neurotrophic NAP analogs targeting metal toxicity and oxidative stress: potential candidates for the control of neurodegenerative diseases.- Acute and chronic effects ofdevelopmental iron deficiency on mRNA expression patterns in the brain.- Long lasting effects of infancy iron deficiency — Preliminary results.- Altered regulation of iron transport and storage in Parkinson’s disease.- Iron dyshomeostasis in Parkinson’s disease.- Cerebral oligemia and iron influence in cerebral structures — element of Morbus Parkinson Models?.- Impact of selenium, iron, copper and zinc in on/off Parkinson’s patients on L-dopa therapy.- Metal specificity of an iron-responsive element in Alzheimer’s APP mRNA 5?untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator.- Green tea catechins as brain-permeable, non toxic iron chelators to “iron out iron” from the brain.